表紙
市場調查報告書

乾癬性關節炎治療藥的全球市場:2019年∼2023年

Global Psoriatic Arthritis Therapeutics Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 895014
出版日期 內容資訊 英文 134 Pages
訂單完成後即時交付
價格
乾癬性關節炎治療藥的全球市場:2019年∼2023年 Global Psoriatic Arthritis Therapeutics Market 2019-2023
出版日期: 2019年07月18日內容資訊: 英文 134 Pages
簡介

全球乾癬性關節炎治療藥市場,在預測期間內預期獲得生物醫藥品優勢的很大恩惠。 2018年,市場收益的80%以上由生物醫藥品銷售帶來。因為大部分市場上市藥喪失了專利,市場主要藥物的生物相似藥的進入增加。因為這些生物相似藥,儘管以低價格販售,市場上認證的小分子藥依然高價格,生物相似藥的進入沒損耗市場價值。再加上生物醫藥品高有效性帶來對生物製藥的高需求,限制小分子藥物的成長。生物醫藥品的優勢,預計導致全球乾癬性關節炎治療藥市場在預測期間內以約9%的年複合成長率擴大。

本報告提供全球乾癬性關節炎治療藥市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 開發平台

第7章 市場區隔:各類型

  • 市場區隔:各類型
  • 各類型比較:市場規模及預測(2018年∼2023年)
  • 生技藥品
  • 小分子
  • 市場機會:各類型

第8章 客戶形勢

第9章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第10章 決策架構

第11章 成長要素與課題

  • 市場成長要素
  • 市場課題

第12章 市場趨勢

  • 再生療法的來到
  • 遺傳基因篩檢檢驗
  • 策略性聯盟的擴大

第13章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭模式

第14章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • AbbVie Inc.
  • Celgene Corp.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.

第15章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第16章 關於TECHNAVIO

目錄
Product Code: IRTNTR31734

About this market

Psoriatic arthritis is an autoimmune disorder that primarily affects psoriasis patients, with approximately 30% of the patient population at risk. Technavio's psoriatic arthritis therapeutics market analysis considers sales from both biologics and small molecules. Our analysis also considers the sales of psoriatic arthritis therapeutics in Asia, Europe, North America, and ROW. In 2018, the biologics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as strong efficacy of approved drugs, availability of patient assistance programs, strong patient pool, and increasing awareness campaigns will play a significant role in the biologics segment to maintain its market position. Also, our global psoriatic arthritis therapeutics market report also looks at factors such as the dominance of biologics, growing awareness of psoriatic arthritis, and strong prevalence. However, difficulty in diagnosis, high treatment costs, and idiopathic nature of the disease may hamper the growth of the psoriatic arthritis therapeutics industry over the forecast period.

Overview

Dominance of biologics

The global psoriatic arthritis therapeutics market is expected to benefit significantly from the strong dominance of biologics during the forecast period. In 2018, over 80% of the market revenue was generated from the sales of biologics. As most of the drugs in the market have lost their patents, the market has witnessed an increase in the entry of biosimilars of major drugs. The entry of biosimilars has not resulted in the value erosion of the market as these biosimilars, despite being priced on the lower end, are still priced higher than the small molecule drugs approved in the market. Moreover, the high efficacy of biologics is resulting in high demand for biologic drugs, which is restricting the growth of small-molecule drugs. The dominance of biologics will lead to the expansion of the global psoriatic arthritis therapeutics market at a CAGR of almost 9% during the forecast period.

The advent of regenerative therapy

The global psoriatic arthritis therapeutics market currently faces a challenge due to the lack of curative therapies for the indication. As psoriatic arthritis is an autoimmune disorder, vendors in the market face a challenge in identifying the pathogenesis of the indication, which is acting as a barrier for the development of a potential cure for the indication. Various vendors and research organizations are conducting research on regenerative therapies such as stem cell therapy for curing psoriatic arthritis. Currently, approximately 25 genetic variants that are responsible for developing psoriatic diseases have been found, including psoriatic arthritis. Though these therapies are still in the early stages and are not expected to receive marketing approval during the forecast period, advances in research are expected to help in the identification of the pathogenesis and the cause of the indication, which can result in the market growth in the coming years.

For the detailed list of factors that will drive the global psoriatic arthritis therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, the global psoriatic arthritis therapeutics market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading psoriatic arthritis therapeutics manufacturers, that include AbbVie Inc., Celgene Corp., Johnson & Johnson Services Inc., Novartis AG, and Pfizer Inc.

Also, the psoriatic arthritis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers s
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Biologics - Market size and forecast 2018-2023
  • Small molecules - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023

Key leading countries

  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Advent of regenerative therapy
  • Genetic screening tests
  • Increasing strategic alliances

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Celgene Corp.
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Global psoriatic arthritis therapeutics market pipeline: Overview
  • Exhibit 19: Global psoriatic arthritis therapeutics market pipeline: Snapshot
  • Exhibit 20: Type - Market share 2018-2023 (%)
  • Exhibit 21: Comparison by type
  • Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Small molecules - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Small molecules - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by type
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Humira biosimilars expected launch in the US
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Vendor landscape
  • Exhibit 47: Landscape disruption
  • Exhibit 48: Vendors covered
  • Exhibit 49: Vendor classification
  • Exhibit 50: Market positioning of vendors
  • Exhibit 51: AbbVie Inc. - Vendor overview
  • Exhibit 52: AbbVie Inc. - Business segments
  • Exhibit 53: AbbVie Inc. - Organizational developments
  • Exhibit 54: AbbVie Inc. - Geographic focus
  • Exhibit 55: AbbVie Inc. - Key offerings
  • Exhibit 56: AbbVie Inc. - Key customers
  • Exhibit 57: Celgene Corp. - Vendor overview
  • Exhibit 58: Celgene Corp. - Business segments
  • Exhibit 59: Celgene Corp. - Organizational developments
  • Exhibit 60: Celgene Corp. - Geographic focus
  • Exhibit 61: Celgene Corp. - Key offerings
  • Exhibit 62: Celgene Corp. - Key customers
  • Exhibit 63: Johnson & Johnson Services Inc. - Vendor overview
  • Exhibit 64: Johnson & Johnson Services Inc. - Business segments
  • Exhibit 65: Johnson & Johnson Services Inc. - Organizational developments
  • Exhibit 66: Johnson & Johnson Services Inc. - Geographic focus
  • Exhibit 67: Johnson & Johnson Services Inc. - Segment focus
  • Exhibit 68: Johnson & Johnson Services Inc. - Key offerings
  • Exhibit 69: Johnson & Johnson Services Inc. - Key customers
  • Exhibit 70: Novartis AG - Vendor overview
  • Exhibit 71: Novartis AG - Business segments
  • Exhibit 72: Novartis AG - Organizational developments
  • Exhibit 73: Novartis AG - Geographic focus
  • Exhibit 74: Novartis AG - Segment focus
  • Exhibit 75: Novartis AG - Key offerings
  • Exhibit 76: Novartis AG - Key customers
  • Exhibit 77: Pfizer Inc. - Vendor overview
  • Exhibit 78: Pfizer Inc. - Business segments
  • Exhibit 79: Pfizer Inc. - Organizational developments
  • Exhibit 80: Pfizer Inc. - Geographic focus
  • Exhibit 81: Pfizer Inc. - Segment focus
  • Exhibit 82: Pfizer Inc. - Key offerings
  • Exhibit 83: Pfizer Inc. - Key customers
  • Exhibit 84: Validation techniques employed for market sizing
  • Exhibit 85: Definition of market positioning of vendors